Anesiva’s Fast-Acting Analgesic Zingo Clears FDA Ahead Of User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking a U.S. partner to aid in the launch of its first drug, CEO says.
You may also be interested in...
Anesiva Reports Positive Phase III Results For Zingo In Adults
Company plans to file for expanded indication in the first quarter of 2008.
Anesiva Reports Positive Phase III Results For Zingo In Adults
Company plans to file for expanded indication in the first quarter of 2008.
Anesiva CEO John P. McLaughlin: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
McLaughlin discusses Anesiva’s newly approved drug Zingo and the firm’s plan to partner the topical local anesthetic in the U.S. and ex-U.S.